Differential Regulation of Plasma Copeptin Levels in Patients with Heart Failure: A Single-Center Prospective Study

Ghandehari

J of Cellular Biochemistry

et al. 2018

Copeptin is a glycosylated peptide derived from the cleavage of the precursor of arginine-vasopressin. In contrast to arginine-vasopressin, copeptin is a stable molecule and can easily be measured using a simple rapid assay. The serum concentration of copeptin is increased in several clinical conditions, including hypertension, chronic kidney disease, and, of special interest in this review, in cardiovascular diseases. The diagnostic and prognostic value of copeptin in different cardiovascular diseases (acute coronary syndrome, stable coronary artery disease, congestive heart failure, and acute ischemic stroke) has been reviewed in this article, to provide an understanding of how its measurement may be applied to improve the management of these conditions.

Section: Congestive Hfmentioning

confidence: 73%

Section: Congestive Hfmentioning

confidence: 81%

The diagnostic and prognostic value of copeptin in cardiovascular disease, current status, and prospective

Ghandehari

J of Cellular Biochemistry

et al. 2018

“…The copeptin level (picomoles per liter) in the medium was detected with a new sandwich immunoassay (Peninsula Laboratories International, San Carlos, CA, USA) after C18 Sep-Column extraction following the manufacturer’s recommendations, as previously reported (12). …”

Section: Methodsmentioning

confidence: 99%

Inhibition of Ectopic Arginine Vasopressin Production by Phenytoin in the Small Cell Lung Cancer Cell Line Lu-165

et al. 2017

Self Cite

Phenytoin, a voltage-gated sodium channel (NaV channel) antagonist, reportedly inhibits arginine vasopressin (AVP) release from an isolated rat neurohypophysis. So far, it is uncertain whether phenytoin has a direct action on ectopic AVP-producing neuroendocrine tumors. We studied the effect of phenytoin on the release of copeptin, the C-terminal fragment of pro-AVP, and expression of AVP gene in the human small cell lung cancer cell line Lu-165. Cells were maintained in RPMI1640 medium with 10% fetal bovine serum and were used within the fifth passage. Copeptin was detected using a new sandwich immunoassay, and AVP mRNA levels were measured using real-time reverse transcription polymerase chain reaction. Treatment with phenytoin at a concentration of 25 µg/mL, but not at 5 or 10 µg/mL, had an inhibitory effect on copeptin levels in the medium at 48 h. At the same concentration, AVP mRNA levels in Lu-165 cells also decreased. Although a sodium challenge with added sodium at 20 mEq/L increased copeptin levels in the medium, a sodium challenge with added sodium at 10 and 20 mEq/L had no effect on AVP mRNA levels. Phenytoin at a concentration of 25 µg/mL suppressed copeptin levels in the medium under the sodium challenge with added sodium at 10 and 20 mEq/L. Phenytoin at a concentration of 25 µg/mL also decreased AVP mRNA levels in Lu-165 cells under the sodium challenge with added sodium at 10 mEq/L, but not at 20 mEq/L. Among five tested NaV channel subunits, NaV1.3 was highly expressed in Lu-165 cells. However, phenytoin significantly decreased NaV1.3 mRNA levels under the sodium challenge with added sodium at 10 and 20 mEq/L. These results suggest that Lu-165 cells are sensitive to phenytoin and sodium to control of AVP release and its gene expression. Phenytoin might have a direct action on ectopic AVP-producing tumors, suggesting the importance of NaV channels in AVP-producing neuroendocrine tumors.

The value of copeptin in the diagnosis and prognosis of cardiovascular diseases

Aliyeva

Алмазова

Pinchuk

et al. 2020

jour

Vasopressin and its receptors play a key role in maintaining homeostasis in physiological and pathophysiological conditions. As a result, the vasopressin system has become an important target for both diagnostic and therapeutic use in a number of diseases. Kopeptin, C-terminal part of vasopressin prohormone. Copeptin has come to be seen as an important marker for identifying high-risk patients and predicting outcomes for various diseases. This improves the clinical value of commonly used biomarkers and risk stratification tools. The area that could benefit most from the introduction of the copeptin measurement in practice is cardiovascular disease. Determination of the level of copeptin becomes a fast and reliable method of differential diagnosis, especially in acute coronary syndromes. A special role in the diagnosis of acute myocardial infarction (AMI) is given to the combination of copeptin and troponin. According to available sources, such a combination eliminates AMI with very high sensitivity and negative predictive value. Moreover, elevated levels of copeptin correlate with poorer prognosis, and a higher risk of side effects after AMI, especially in patients with heart failure.